Le Lézard
Classified in: Health
Subject: TRI

A New Source of Cells for Treating Blindness


WASHINGTON, Jan. 18, 2021 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 246, Issue 2, January, 2021) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220963755) reports a cell replacement therapy for blindness caused by loss of photoreceptors. The study, led by Dr. Jian Feng, Professor of Physiology and Biophysics, State University of New York at Buffalo in New York (USA), demonstrates that adult human retinal pigment cells can be converted to neurons that exhibit many properties of photoreceptors.

Photoreceptor degeneration is a leading cause of blindness. Photoreceptors are specialized neurons in the retina that allow us to see by converting the information in light into signals for transmission to the brain. Because photoreceptors are neurons, the body cannot generate new photoreceptors after injury. One alternative is transplantation of photoreceptors generated in a dish into the retina. Human retinal pigment epithelial cells are readily available from organ donors and originate from the same structure during development as photoreceptors. While their proliferative potential and ability to transdifferentiate into other cell types make them an attractive source, there are no established methods for converting retinal pigment epithelial cells into photoreceptors.

In this study, Feng and colleagues examined the ability of the transcription factor ASCL1 and gene expression regulator miRNA124 to convert human retinal pigment epithelial cells to neurons. After 10 days of treatment, retinal pigment epithelial cells exhibited many properties of photoreceptors including expression of photoreceptor-specific genes and production of membrane stacks similar to photoreceptor discs. Although the converted neurons did not respond to light stimulation, this study paves the way for further developments that may generate light-responsive photoreceptors suitable for transplantation. Dr. Feng said, "It is quite remarkable that adult human retinal pigment epithelial cells from donated retinas can be used to make neurons with many properties of photoreceptors. This promising method may eventually produce functional photoreceptors that can be used to cure blindness."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said, "Dr. Feng and colleagues have taken a major step towards a cell-based therapy for photoreceptor degeneration that leads to blindness, in being able to convert primary adult human retinal pigmented epithelium (hRPE) into post mitotic neurons with several properties of photoreceptors. Future studies will focus creating photoreceptors with all components required for light sensitivity."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit www.sebm.org. If you are interested in publishing in the journal, please visit http://ebm.sagepub.com/.

Related Images

image1.png

 

SOURCE Experimental Biology and Medicine


These press releases may also interest you

at 09:15
101 Mobility® is thrilled to announce the opening of its newest location in Eden Prairie, marking the introduction of the city's first nationally branded full-service provider of a wide range of mobility equipment. This includes stair lifts, ramps,...

at 09:15
Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health.This approval enables Vibrant...

at 09:07
Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the...

at 09:05
Adolescence isn't just a phase; it's a time of unparalleled growth and an opportunity for developing strengths that will influence our adult lives. Recognizing the potential of this developmental stage, Committee for Children a global nonprofit and...

at 09:00
The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp , a global leader of innovative diagnostic and biopharma laboratory services, to serve as its...

at 09:00
LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies,...



News published on and distributed by: